Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock

When billionaire investors step into a particular smaller-cap under-the-radar name, investors take notice. That appears to be the case with Fate Therapeutics (NASDAQ:FATE) today. At the time of writing, FATE stock has soared more than 17% on news that Steve Cohen and his Point 72 hedge fund have taken a 5% passive stake in the biotech company.Fate Therapeutics is working on developing drugs and treatments for patients with various cancers and autoimmune diseases. The early-stage oncology and immune biotech ...